Moderna seeks EUA for kids under 6 years with high survival rate & low vaccine efficacy results

Moderna submits emergency use authorization application to Canada and the U.S. for their COVID-19 vaccine in children 6 months to under 6 years with a 37% to 51% vaccine efficacy rate after two doses, children have a 99.9% survival rate in this age group.

Sources,

https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx

https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html

https://covid.cdc.gov/covid-data-tracker/#demographics